The affirmation of the Market Outperform rating suggests that JMP Securities remains optimistic about Aura Biosciences' prospects. However, the reduction in the price target may reflect a reassessment of the growth potential or risks associated with the company, which could lead to a neutral short-term impact on the stock as investors digest the mixed signals.